NASDAQ:RKDA Arcadia Biosciences (RKDA) Stock Price, News & Analysis $4.22 +0.04 (+0.84%) Closing price 05/23/2025 03:40 PM EasternExtended Trading$4.22 +0.01 (+0.24%) As of 05/23/2025 06:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Arcadia Biosciences Stock (NASDAQ:RKDA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Arcadia Biosciences alerts:Sign Up Key Stats Today's Range$4.21▼$4.2950-Day Range$2.67▼$4.3952-Week Range$2.40▼$10.31Volume3,624 shsAverage Volume310,433 shsMarket Capitalization$5.76 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingBuy Company OverviewArcadia Biosciences, Inc. produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring. The company was incorporated in 2002 and is headquartered in Dallas, Texas.Read More… Arcadia Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreRKDA MarketRank™: Arcadia Biosciences scored higher than 40% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingArcadia Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageArcadia Biosciences has received no research coverage in the past 90 days.Read more about Arcadia Biosciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcadia Biosciences is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcadia Biosciences is -0.98, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArcadia Biosciences has a P/B Ratio of 0.37. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Arcadia Biosciences' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.90% of the float of Arcadia Biosciences has been sold short.Short Interest Ratio / Days to CoverArcadia Biosciences has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arcadia Biosciences has recently decreased by 7.58%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArcadia Biosciences does not currently pay a dividend.Dividend GrowthArcadia Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.90% of the float of Arcadia Biosciences has been sold short.Short Interest Ratio / Days to CoverArcadia Biosciences has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Arcadia Biosciences has recently decreased by 7.58%, indicating that investor sentiment is improving significantly. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Arcadia Biosciences this week, compared to 1 article on an average week.Search Interest3 people have searched for RKDA on MarketBeat in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Arcadia Biosciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Arcadia Biosciences is held by insiders.Percentage Held by InstitutionsOnly 17.73% of the stock of Arcadia Biosciences is held by institutions.Read more about Arcadia Biosciences' insider trading history. Receive RKDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcadia Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address RKDA Stock News HeadlinesRKDA Arcadia Biosciences, Inc.May 24 at 4:14 PM | seekingalpha.comArcadia Biosciences (NASDAQ:RKDA) Coverage Initiated by Analysts at StockNews.comMay 19, 2025 | americanbankingnews.comThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, it surged 239%. And in 2024, it soared another 171% on the year… But what if I told you there was a way to target those types of “peak Nvidia” profit opportunities in 24 hours or less?May 25, 2025 | Timothy Sykes (Ad)Arcadia Biosciences, Inc. (RKDA) Q1 2025 Earnings Call TranscriptMay 11, 2025 | seekingalpha.comARCADIA BIOSCIENCES Earnings Results: $RKDA Reports Quarterly EarningsMay 10, 2025 | nasdaq.comArcadia Biosciences, Inc. (NASDAQ:RKDA) Q1 2025 Earnings Call TranscriptMay 10, 2025 | msn.comArcadia Biosciences Inc (RKDA) Q1 2025 Earnings Call Highlights: Strong Zola Sales and ...May 9, 2025 | finance.yahoo.comArcadia Biosciences, Inc.: Arcadia Biosciences (RKDA) Announces First Quarter 2025 Financial Results and Business HighlightsMay 8, 2025 | finanznachrichten.deSee More Headlines RKDA Stock Analysis - Frequently Asked Questions How have RKDA shares performed this year? Arcadia Biosciences' stock was trading at $5.92 on January 1st, 2025. Since then, RKDA shares have decreased by 28.8% and is now trading at $4.2150. View the best growth stocks for 2025 here. How were Arcadia Biosciences' earnings last quarter? Arcadia Biosciences, Inc. (NASDAQ:RKDA) posted its quarterly earnings data on Thursday, May, 8th. The basic materials company reported $1.90 EPS for the quarter, topping the consensus estimate of ($0.98) by $2.88. The basic materials company had revenue of $1.20 million for the quarter, compared to analyst estimates of $1.60 million. Arcadia Biosciences had a negative trailing twelve-month return on equity of 52.63% and a negative net margin of 110.61%. Read the conference call transcript. When did Arcadia Biosciences' stock split? Shares of Arcadia Biosciences reverse split on Wednesday, January 24th 2018. The 1-20 reverse split was announced on Tuesday, January 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 23rd 2018. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Arcadia Biosciences IPO? Arcadia Biosciences (RKDA) raised $66 million in an IPO on Friday, May 15th 2015. The company issued 8,200,000 shares at a price of $8.00 per share. Credit Suisse, J.P. Morgan and Piper Jaffray acted as the underwriters for the IPO. How do I buy shares of Arcadia Biosciences? Shares of RKDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Arcadia Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Arcadia Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), PayPal (PYPL), GE Aerospace (GE), Arista Networks (ANET), Advanced Micro Devices (AMD) and CrowdStrike (CRWD). Company Calendar Last Earnings5/08/2025Today5/25/2025Next Earnings (Estimated)8/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorBasic Materials Industry Agricultural production - crops Sub-IndustryAgriculture Current SymbolNASDAQ:RKDA CIK1469443 Webwww.arcadiabio.com Phone(530) 756-7077Fax530-756-7027Employees60Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+42.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($4.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-13,980,000.00 Net Margins-110.61% Pretax Margin-156.15% Return on Equity-52.63% Return on Assets-34.57% Debt Debt-to-Equity RatioN/A Current Ratio4.60 Quick Ratio4.24 Sales & Book Value Annual Sales$5.26 million Price / Sales1.10 Cash FlowN/A Price / Cash FlowN/A Book Value$11.44 per share Price / Book0.37Miscellaneous Outstanding Shares1,367,000Free Float1,340,000Market Cap$5.76 million OptionableNot Optionable Beta0.35 Social Links 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.Get This Free Report This page (NASDAQ:RKDA) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bitcoin's supply is being drained at unprecedented rates, but while most investors focus solely on Bitcoin, th...Crypto 101 Media | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Arcadia Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Arcadia Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.